Penumbra, Inc.
PEN · New York Stock Exchange · USD
321,85USD
+2,64 (+0,83 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 319,00
- Vortag
- 319,21
- Tagesspanne
- 319,00 – 322,90
- 52 Wochen
- 262,94 – 362,41
- Volumen
- 251.250
- Ø Volumen
- 357.757
- Börsenwert
- 12,69 Mrd. $
- KGV
- 80,7
- Gewinn je Aktie (TTM)
- 3,97
- Dividendenrendite
- 0,0 %
- Beta
- 0,7
- Nächste Zahlen
- 24. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 1,4 Mrd. | 1,19 Mrd. | 1,06 Mrd. | 847,13 Mio. | 747,59 Mio. |
| Herstellungskosten | 461,23 Mio. | 439,62 Mio. | 375,88 Mio. | 311,93 Mio. | 272,21 Mio. |
| Bruttogewinn | 942,44 Mio. | 755 Mio. | 682,64 Mio. | 535,21 Mio. | 475,38 Mio. |
| Forschung und Entwicklung | 89,77 Mio. | 94,78 Mio. | 84,42 Mio. | 79,41 Mio. | 104,55 Mio. |
| Vertrieb und Verwaltung | 663,42 Mio. | 573,99 Mio. | 506,45 Mio. | 449,72 Mio. | 378,33 Mio. |
| Operatives Ergebnis | 189,25 Mio. | 86,22 Mio. | 73,55 Mio. | 6,08 Mio. | −7,5 Mio. |
| EBITDA | 223,91 Mio. | 45,99 Mio. | 108,65 Mio. | 29,96 Mio. | 7,84 Mio. |
| Nettogewinn | 177,69 Mio. | 14,01 Mio. | 90,95 Mio. | −2 Mio. | 5,28 Mio. |
| Gewinn je Aktie (verwässert) | 4,52 | 0,36 | 2,32 | -0,05 | 0,14 |
Umsatz nach Segment
Produkte · FY 2022
- Peripheral Vascular499,39 Mio. $58,95 %+22,14 %
- Neuro347,74 Mio. $41,05 %+2,67 %
Anteil · ggü. Vorjahr (FY 2021)
Regionen · FY 2025
- UNITED STATES1,09 Mrd. $77,78 %+21,03 %
- Non-US311,9 Mio. $22,22 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 80,7
- Kurs-Umsatz-Verhältnis
- 8,1
- Kurs-Buchwert-Verhältnis
- 8,0
- PEG
- -13,7
- Bruttomarge
- 68,0 %
- Operative Marge
- 12,1 %
- Nettomarge
- 10,1 %
- Verschuldungsgrad
- 0,1
- EV/EBITDA
- 55,1
- Eigenkapitalrendite
- 10,4 %
- Kapitalrendite (ROIC)
- 7,9 %
- Free-Cashflow-Rendite
- 1,6 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 67,1 % | 63,2 % | 64,5 % | 63,2 % | 63,6 % |
| Operative Marge | 13,5 % | 7,2 % | 6,9 % | 0,7 % | −1,0 % |
| Nettomarge | 12,7 % | 1,2 % | 8,6 % | −0,2 % | 0,7 % |
| KGV | 68,0 | 659,7 | 106,1 | -4.205,3 | 2.052,3 |
| Kurs-Umsatz-Verhältnis | 8,6 | 7,7 | 9,1 | 9,9 | 14,1 |
| Kurs-Buchwert-Verhältnis | 8,5 | 8,0 | 8,2 | 8,4 | 11,1 |
| Verschuldungsgrad | 0,2 | 0,2 | 0,2 | 0,2 | 0,2 |
| Liquidität 3. Grades | 6,6 | 6,0 | 6,1 | 5,2 | 5,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 12,13 Mrd. | 9,07 Mrd. | 9,73 Mrd. | 8,58 Mrd. | 10,68 Mrd. |
| EV/EBITDA | 54,2 | 197,3 | 89,5 | 286,5 | 1.362,1 |
| Eigenkapitalrendite | 12,4 % | 1,2 % | 7,7 % | −0,2 % | 0,6 % |
| Kapitalrendite (ROIC) | 9,9 % | 4,2 % | 5,2 % | −0,3 % | 0,2 % |
| Free-Cashflow-Rendite | 1,4 % | 1,6 % | 0,9 % | −0,9 % | −0,1 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +17,5 % | +12,9 % | +25,0 % | +13,3 % | +33,4 % |
| Bruttogewinn | +24,8 % | +10,6 % | +27,5 % | +12,6 % | +40,6 % |
| Operatives Ergebnis | +119,5 % | +17,2 % | +1.109,3 % | +181,1 % | +80,7 % |
| Nettogewinn | +1.168,1 % | −84,6 % | +4.643,2 % | −137,9 % | +133,7 % |
| Gewinn je Aktie | +1.155,6 % | −84,5 % | +4.485,6 % | −137,8 % | +125,9 % |
| Freier Cashflow | +18,8 % | +79,4 % | +209,6 % | −541,9 % | +79,9 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 9Kaufen
- 13Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
320,00
Durchschnitt · −0,57 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 1,6 Mrd. | 1,81 Mrd. | 2,04 Mrd. |
| Umsatz (Tief – Hoch) | 1,57 Mrd. – 1,61 Mrd. | 1,78 Mrd. – 1,83 Mrd. | 1,94 Mrd. – 2,08 Mrd. |
| Gewinn je Aktie (Ø) | 4,66 | 5,94 | 6,93 |
| Gewinn je Aktie (Tief – Hoch) | 4,48 – 4,84 | 5,29 – 6,59 | 6,60 – 7,35 |
| Analysten | 5 | 6 | 4 |
Letzte Änderungen
- Evercore ISI Group6. Juli 2026Outperform
- RBC Capital11. Juni 2026Sector Perform
- Evercore ISI Group7. Mai 2026Outperform
- Citigroup7. Mai 2026Neutral
- Evercore ISI Group26. Feb. 2026Outperform
- RBC Capital20. Jan. 2026Outperform → Sector Perform
- Canaccord Genuity20. Jan. 2026Buy → Hold
- Leerink Partners16. Jan. 2026Outperform → Market Perform
Quartalszahlen
Nächste Zahlen: 24. Feb. 2027| Okt. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 1,20 | 1,16 | 1,04 | 1,11 | 0,93 | 0,81 | 0,66 | 0,88 |
| Gewinn je Aktie · Tatsächlich | 1,07 | 0,88 | 0,82 | 1,18 | 0,97 | 0,86 | 0,83 | 0,97 |
| Abweichung | −10,83 % | −24,14 % | −21,15 % | +6,31 % | +4,41 % | +6,17 % | +25,76 % | +10,23 % |
| Umsatz · Tatsächlich | 410,15 Mio. | 390,05 Mio. | 374,76 Mio. | 385,39 Mio. | 354,69 Mio. | 339,46 Mio. | 324,14 Mio. | 315,52 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 16. Nov. 20141:10
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 87,80 %
- Investoren mit 13F-Meldung
- 476
Größte Investoren
- BLACKROCK, INC.10,93 %4,3 Mio.
- HBK INVESTMENTS L P4,68 %1,84 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,35 %1,71 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,24 %1,67 Mio.
- STATE STREET CORP3,17 %1,24 Mio.
- EXODUSPOINT CAPITAL MANAGEMENT, LP2,77 %1,09 Mio.
- BALYASNY ASSET MANAGEMENT L.P.2,77 %1,09 Mio.
- JPMORGAN CHASE & CO2,73 %1,07 Mio.
Insider-Geschäfte
- Narayan Shruthi15. Okt. 2026 · officer: PresidentVerkauf1367 Aktien · 321,20
- Narayan Shruthi15. Sept. 2026 · officer: PresidentVerkauf1230 Aktien · 318,43
- Narayan Shruthi17. Aug. 2026 · officer: PresidentKauf3060 Aktien
- Elsesser Adam19. Mai 2026 · director, officer: CEOVerkauf77.000 Aktien
- Grewal Harpreet2. Apr. 2026 · directorVerkauf100 Aktien · 328,22
- Narayan Shruthi15. März 2026 · officer: PresidentVerkauf117 Aktien · 336,18
- Roberts Johanna15. März 2026 · officer: EVP, Gen. Counsel & SecretaryVerkauf186 Aktien · 336,18
- Yuen Maggie15. März 2026 · officer: Chief Financial OfficerVerkauf186 Aktien · 336,18
Vergleichbare Unternehmen
ABTAbbott Laboratories110,53+0,55 %
ANGOAngioDynamics, Inc.12,12+3,32 %
BSXBoston Scientific Corporation44,02+2,97 %
EWEdwards Lifesciences Corporation104,71+2,52 %
ISRGIntuitive Surgical, Inc.460,56+1,71 %
LMATLeMaitre Vascular, Inc.81,16+0,33 %
MDTMedtronic Plc102,79+0,97 %
MMSIMerit Medical Systems, Inc.88,42+1,36 %
Über das Unternehmen
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Führung
- Adam ElsesserCo-Founder, Chairman & Chief Executive Officer
- Shruthi NarayanPresident
- Maggie S. YuenChief Financial Officer
- Johanna RobertsExecutive Vice President, General Counsel & Secretary
- Lambert ShiuChief Accounting Officer
- Arani BoseCo-Founder & Director
- CEO
- Adam Elsesser
- Mitarbeitende
- 4.700
- Hauptsitz
- Alameda, CA, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 18. Sept. 2015
- Website
- penumbrainc.com
Nachrichten
- PRNewsWire · 29. Okt., 16:05Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- PRNewsWire · 20. Okt., 9:00Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
- Defense World · 17. Okt., 3:21Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?
- PRNewsWire · 6. Okt., 9:00New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
- Zacks Investment Research · 1. Okt., 12:41IART vs. PEN: Which Stock Is the Better Value Option?
- Defense World · 30. Sept., 2:42Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?
- Zacks Investment Research · 29. Sept., 12:41IART or PEN: Which Is the Better Value Stock Right Now?
- Zacks Investment Research · 16. Sept., 10:15Reasons to Retain Penumbra Stock in Your Portfolio for Now
- Zacks Investment Research · 11. Sept., 12:40TFX vs. PEN: Which Stock Is the Better Value Option?
- Defense World · 30. Aug., 4:23Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.